Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Pfizer’s Hemophilia Treatment Marstacimab Accepted for Review in China

Fineline Cube Aug 13, 2024

The China Center for Drug Evaluation (CDE) has accepted for review a market approval filing...

Company Drug

Junshi Biosciences Submits Twelfth Indication for PD-1 Inhibitor Loqtorzi in China

Fineline Cube Aug 13, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a new indication filing...

Company Drug

Nanjing Sanhome’s Oritinib Ships Widely for EGFR-mutated NSCLC Treatment in China

Fineline Cube Aug 13, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd, a notable player in the pharmaceutical sector, has announced the...

Company Drug

Boehringer Ingelheim’s Zongertinib Earns Breakthrough Designation in China for HER2-Mutated NSCLC

Fineline Cube Aug 13, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has received a significant endorsement from China’s Center...

Legal / IP Policy / Regulatory

China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry

Fineline Cube Aug 13, 2024

The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment

Fineline Cube Aug 13, 2024

IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...

Company Drug

Ascendis Pharma’s Hypoparathyroidism Therapy Yorvipath Wins FDA Nod, Fills Market Gap

Fineline Cube Aug 13, 2024

This week, the U.S. Food and Drug Administration (FDA) granted market approval to Ascendis Pharma...

Company Deals

Siemens Healthineers Partners with Cedars-Sinai to Boost Medical Cooperation and Education

Fineline Cube Aug 13, 2024

Siemens Healthineers AG, a global leader in medical technology, has announced a strategic partnership with...

Company Medical Device

Artech Medical’s Balloon Cryoablation Catheter Wins NMPA Nod for Atrial Fibrillation Treatment

Fineline Cube Aug 13, 2024

Shanghai Artech Medical Technology Co., Ltd., a company known for its innovation in the medical...

Hospital

Former Hainan Medical University President Li Jingquan Expelled for Serious Disciplinary Violations

Fineline Cube Aug 13, 2024

Hainan’s disciplinary inspection committee has announced the expulsion of Li Jingquan, the former president of...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Shows Strong Protection in Immunocompromised Adults, Phase III Sub-Study Reveals

Fineline Cube Aug 13, 2024

Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline...

Company Deals

TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion

Fineline Cube Aug 12, 2024

TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial...

Company Drug

Chinese NMPA Approves Hengrui Pharmaceuticals’ Generic Abraxane for Metastatic Pancreatic Cancer Treatment

Fineline Cube Aug 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Mindray Medical Forges Comprehensive Partnership with CUHK-Shenzhen School of Medicine

Fineline Cube Aug 12, 2024

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a prominent medical device company based in...

Company Drug

CSPC Pharmaceutical’s SYS6020 Receives NMPA Approval for Clinical Trials in Systemic Lupus Erythematosus

Fineline Cube Aug 12, 2024

CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company in China, has announced that...

Company Drug

Mabwell’s Nectin-4 Targeting ADC 9MW2821 on Path to Breakthrough Designation in China for Urothelial Carcinoma

Fineline Cube Aug 12, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Shineyo Medical Secures RMB 100 Million in Series A+ Funding for Cardiac and Vascular Devices

Fineline Cube Aug 12, 2024

Shineyo Medical, a Shanghai-based manufacturer of electrophysiological and peripheral interventional devices, has reportedly secured nearly...

Company Drug

Fujian Cosunter’s Innovative Drug GST-HG141 Exceeds Efficacy in Reducing HBV DNA in Phase II Study

Fineline Cube Aug 12, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced the successful...

Company Drug

3SBio Subsidiary Achieves Milestone in Phase III Psoriasis Trial with SSGJ-608

Fineline Cube Aug 12, 2024

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced...

Company Drug

Guangdong Zhongsheng Pharmaceutical’s COVID-19 Drug Leritrelvir Approved in Macau

Fineline Cube Aug 12, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a pharmaceutical company based in China, has announced...

Posts pagination

1 … 310 311 312 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.